A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 1, 2015

Primary Completion Date

August 1, 2017

Study Completion Date

June 12, 2018

Conditions
Subdural Hematoma
Interventions
DRUG

Tranexamic Acid

1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first

Trial Locations (1)

85013

Barrow Brain and Spine, Phoenix

All Listed Sponsors
collaborator

Barrow Neurological Foundation

OTHER

lead

St. Joseph's Hospital and Medical Center, Phoenix

OTHER

NCT02618382 - A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population | Biotech Hunter | Biotech Hunter